Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ionova Life Science

Request full access

A biomedical company that leads technological innovation and benefits human health

Shenzhen, ChinaFounded 2016Biotech & Life Sciences

About Ionova Life Science

Ionova Life Science is a clinical-stage biotechnology company located in the Guangdong-Hong Kong-Macao Greater Bay Area of China, established in November 2016. The company was founded by Dr. Yongkui Sun, a scientist with over 20 years of experience in research and development at Merck Research Laboratories and a member of the US National Academy of Engineering. Dr. Sun's extensive background in the pharmaceutical industry underpins the company's core mission.

The firm concentrates on the development of a new generation of targeted immunotherapies for cancer treatment. Its operational strategy is centered on translating discoveries in basic biomedical research into novel drugs with distinct clinical advantages. Ionova's business model involves in-house drug discovery and development, supplemented by collaborations with academic and industrial partners through its research division, the Touchstone Translational Research Institute. The company's revenue generation is tied to the progression of its drug candidates through clinical trials and eventual commercialization, a long-term strategy typical of the biotechnology sector. This is supported by significant venture capital funding.

Ionova Life Science has built a robust pipeline of drug candidates aimed at combating cancers and addressing cancer resistance. A key focus area since its inception has been research into the tumor microenvironment and immunoregulation. The company's product development strategy combines immunotherapy with targeted therapy to create synergistic effects. One of its leading candidates, INV-1120, has entered Phase I clinical trials in the United States. The company has secured substantial funding to advance its portfolio, including a $17 million Series A in October 2019 and a $100 million financing round in August 2021, which supports the progression of its preclinical and clinical oncology candidates.

Source: Dealroom company data

At a glance

Status
Operational
Employees
15
Open positions
None listed
Dealroom signal
42.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Aug 2021 $100M $400M Lilly Asia Ventures · Shenzhen Capital Group · Tsing Capital · Dyee Capital —
SERIES AOther financing Oct 2019 $18M $71M Dyee Capital · Lilly Asia Ventures —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Ionova Life Science website traffic

Latest recorded traffic for Ionova Life Science is 1.5K monthly website visits, up 64.8% over the last three months. Ionova Life Science's team grew 7.1% over the past year.

Latest monthly visits1.5K 3-month web change+64.8% 1-year team growth+7.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Ionova Life Science in the Shenzhen ecosystem

Live from Dealroom

The Ionova Life Science office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China77.8%
🇺🇸 United States22.2%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ionova Life Science on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ionova Life Science’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.